DGAP-Adhoc: BB Biotech AG closes the 2021 fiscal year with a loss

2022. január 21., péntek, 07:00





DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Preliminary Results


BB Biotech AG closes the 2021 fiscal year with a loss


21-Jan-2022 / 07:00 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules


January 21, 2022



BB Biotech AG closes the 2021 fiscal year with a loss



In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for its financial year 2021.



Based on its preliminary unaudited consolidated figures, BB Biotech AG reports a loss of approximately CHF 405 million for the financial year 2021 (profit of CHF 691 million in the previous year). For an investment company, the results reflect the share price development of the companies held in the portfolio.



The publication of all relevant portfolio data will take place on January 21, 2022 at 7:00 am and the complete annual report will be published on February 18, 2022.



For further information:



Media Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00

Tanja Chicherio, tch@bellevue.ch


www.bbbiotech.com


Company profile



BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe. BB Biotech AG is one of the leading investors in this sector. BB Biotech AG builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions.











21-Jan-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

























Language: English
Company: BB BIOTECH AG

Schwertstrasse 6

8200 Schaffhausen

Switzerland
Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Mailand, SIX
EQS News ID: 1270962





 
End of Announcement DGAP News Service




1270962  21-Jan-2022 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=1270962&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.